Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) EBITDA (2016 - 2025)

Historic EBITDA for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$17.8 million.

  • Karyopharm Therapeutics' EBITDA rose 4295.58% to -$17.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$90.7 million, marking a year-over-year increase of 2405.83%. This contributed to the annual value of -$90.7 million for FY2025, which is 2405.83% up from last year.
  • As of Q4 2025, Karyopharm Therapeutics' EBITDA stood at -$17.8 million, which was up 4295.58% from -$15.2 million recorded in Q3 2025.
  • Karyopharm Therapeutics' EBITDA's 5-year high stood at $47.0 million during Q4 2021, with a 5-year trough of -$52.4 million in Q1 2021.
  • Over the past 5 years, Karyopharm Therapeutics' median EBITDA value was -$31.3 million (recorded in 2023), while the average stood at -$29.0 million.
  • Per our database at Business Quant, Karyopharm Therapeutics' EBITDA surged by 22669.83% in 2021 and then crashed by 17212.0% in 2022.
  • Over the past 5 years, Karyopharm Therapeutics' EBITDA (Quarter) stood at $47.0 million in 2021, then plummeted by 172.12% to -$33.9 million in 2022, then dropped by 11.63% to -$37.8 million in 2023, then rose by 17.26% to -$31.3 million in 2024, then surged by 42.96% to -$17.8 million in 2025.
  • Its EBITDA stands at -$17.8 million for Q4 2025, versus -$15.2 million for Q3 2025 and -$24.4 million for Q2 2025.